Krystal Biotech (NASDAQ:KRYS) Given Buy Rating at HC Wainwright

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They presently have a $200.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 23.64% from the company’s current price.

A number of other equities research analysts also recently issued reports on KRYS. Citigroup boosted their price target on Krystal Biotech from $160.00 to $195.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. William Blair reaffirmed an “outperform” rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Guggenheim lifted their target price on shares of Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $204.00 price target (up from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $171.00.

Krystal Biotech Stock Up 3.1 %

KRYS stock opened at $161.76 on Monday. The stock’s fifty day simple moving average is $168.87 and its 200-day simple moving average is $134.11. Krystal Biotech has a 52-week low of $83.38 and a 52-week high of $189.97. The stock has a market capitalization of $4.61 billion, a price-to-earnings ratio of 2,022.25 and a beta of 0.91.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, May 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by ($0.17). The company had revenue of $45.25 million for the quarter, compared to analyst estimates of $47.37 million. The business’s revenue was up 452400.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.76) earnings per share. As a group, analysts anticipate that Krystal Biotech will post 1.82 earnings per share for the current fiscal year.

Insider Activity

In related news, CAO Kathryn Romano sold 8,087 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $136.91, for a total value of $1,107,191.17. Following the completion of the sale, the chief accounting officer now directly owns 12,556 shares of the company’s stock, valued at $1,719,041.96. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the transaction, the insider now directly owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Kathryn Romano sold 8,087 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $136.91, for a total transaction of $1,107,191.17. Following the completion of the transaction, the chief accounting officer now directly owns 12,556 shares in the company, valued at approximately $1,719,041.96. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 38,087 shares of company stock worth $6,210,591. 14.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Jennison Associates LLC lifted its holdings in Krystal Biotech by 112.5% in the fourth quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock worth $89,862,000 after purchasing an additional 383,495 shares during the period. TimesSquare Capital Management LLC bought a new position in Krystal Biotech during the 3rd quarter valued at $14,272,000. Charles Schwab Investment Management Inc. increased its position in shares of Krystal Biotech by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 179,780 shares of the company’s stock valued at $20,854,000 after purchasing an additional 17,614 shares during the period. Vanguard Group Inc. raised its stake in shares of Krystal Biotech by 40.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company’s stock worth $278,416,000 after buying an additional 693,852 shares in the last quarter. Finally, Trexquant Investment LP lifted its holdings in shares of Krystal Biotech by 8.8% in the third quarter. Trexquant Investment LP now owns 8,113 shares of the company’s stock valued at $941,000 after buying an additional 657 shares during the period. 86.29% of the stock is currently owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).